Title: Artificial Intelligence Empowering Innovative Drug Development

Date & Time: November 18, 2024 (Monday), 9:00-10:00 AM

Location: Multipurpose Hall, 2nd Floor, Wang Changlai Building, Ningbo University Health Science Center

Speaker: Dr. Weidong Xie

Biography:

Dr. Weidong Xie graduated from Imperial College London in 1986 and is a senior member of the American Society of Clinical Oncology (ASCO), American Association for Cancer Research (AACR), and American Society for Virology (ASV). He focuses on technological innovation, investment, and management within the biotechnology and pharmaceutical industries, accumulating over 30 years of extensive experience in drug development. Dr. Xie has served as an Associate Professor at the Bioengineering Center of Sun Yat-sen University in Guangzhou, R&D Manager at Novopharm Biotech Inc. in Canada, PI and Director of the Immunoglobulin R&D Center at St. Jude Children's Research Hospital in the United States, and Medical R&D Director at Cheung Kong Life Sciences Group under Li Ka-shing.

Dr. Xie is also a professional expert in investment management within the biopharmaceutical field. During his tenure at Cheung Kong Life Sciences International Group, he managed an R&D team of over 40 members. He has also served as a director at POLYNOMA Biological Corporation in the United States and Investment Director at Zhongshi Venture Capital Fund for Biomedicine in Canada. With extensive experience in transnational technology transfer of drugs, he is proficient in the full process management of drug development applications across China, the United States, Australia, and other countries and regions.

Since 2018, Dr. Xie and his team have applied artificial intelligence to establish AI cancer pathology diagnosis through deep learning and large models. They have also developed a small molecule screening system using Google’s Alphafold and David Baker’s protein prediction technologies, and have quickly identified several candidate drug molecules using this system. Dr. Xie has published nearly 60 papers in both Chinese and English and holds 8 patents in China, the United States, and Europe.